Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
about
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesInhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation.Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.Use of monoclonal antibodies in renal transplantation.CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexesCD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice.Pathogenesis of human systemic lupus erythematosus: recent advances.Platelets and their chemokines in atherosclerosis-clinical applications.Advances in graft-versus-host disease biology and therapy.T cells as therapeutic targets in SLE.Costimulatory pathways in transplantation.A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.Immunosuppressive Medications.Local administration of soluble CD40:Fc to the salivary glands of non-obese diabetic mice does not ameliorate autoimmune inflammation.Abnormalities of T cell signaling in systemic lupus erythematosus.In-/off-label use of biologic therapy in systemic lupus erythematosus.Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedsideAssociation between serum soluble CD40 ligand levels and mortality in patients with severe sepsis.T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.Lupus nephritis: a review of the current pharmacological treatments.T cell tolerance induced by therapeutic antibodiesChemokines and their receptors in islet allograft rejection and as targets for tolerance induction.B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritisTargeting of the immune system in systemic lupus erythematosus.Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis.Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation.Autoimmune manifestations in aged mice arise from early-life immune dysregulation.Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.Autoantibodies in neuromuscular autoimmune disorders.Blocking costimulatory pathways: prospects for inducing transplantation tolerance.Abatacept in the treatment of lupus.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Costimulatory pathways in kidney transplantation: pathogenetic role, clinical significance and new therapeutic opportunities.Tolerance--is it worth it?What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis.Biologics for the treatment of autoimmune renal diseases.
P2860
Q27690917-727FF627-7430-4C7F-BE51-F55BAA790631Q30849102-1B10A068-1842-4E05-81D5-9809245C7262Q33375992-AB5C3F88-DF4D-48CC-B1B1-4974D273BE95Q33396236-91774780-125F-4EF0-B0F2-DACF9492B9ECQ33418006-2D7CC4C7-7418-4841-AC3E-9FA84DF8216AQ33426121-148202D0-A7E2-4029-AFB0-D99D6E7A72FCQ33664927-6E1825FE-EBCC-49C6-8BC9-D97D5887DD4EQ34019069-E2F7A901-7E89-4AE1-A97A-4C277D1CF623Q34031916-B06D99AE-3761-4D9E-8520-890A868F3D9CQ34075552-EEF78C47-655A-4DD4-8563-8231253462ADQ34187594-DB5DA352-2428-476A-80F3-B1FCB1D90563Q34283011-722E0939-5A55-4D09-8B9A-47CA9332474EQ34484801-FD718C2B-92B3-4215-8069-2C8392C7DB0DQ34540139-9356BA97-7CA5-44A7-AC3A-3FA8616C4CEFQ35092855-E339CB86-4AD5-45D8-A6B3-15C1BDB77A03Q35094536-7498E832-3F68-4996-BF09-1461CB3EC519Q35221271-B5729483-7D18-4F4E-9145-79EE60E105C6Q35309470-156CE4A3-4DC8-4E3E-ACD5-1725D4838B41Q35559467-1A62769E-044A-4B05-8ADC-10E67472A130Q35836112-BED6CBAC-CD3C-4B60-8673-46B97886ACF2Q35925513-10184D57-0AD6-45DC-881D-0BA2E37F0696Q36251293-833AF77B-5D17-4FD0-88AC-47E693E70C43Q36560836-044178B0-1174-4125-BE5B-1590BE5E7E3EQ36577391-1B910667-A344-4DE9-9830-AD4B86E69993Q36726316-FCD45F38-D2E9-4C06-A6BF-1F08A6C628B6Q37060593-89DB576A-729D-4535-B308-8451D0320D65Q37300823-4A8733EA-7E67-4001-82A8-83030087014EQ37412470-F2CFDBC9-DA6F-49E6-B673-5B7AB52F30F8Q37624299-4A2890B6-F196-45E4-BD4F-2F06E9E9FFF0Q37625670-1ECEE401-318A-44A8-A55F-99829A0C0DFBQ37754738-574CA658-0CFD-41B5-B711-60F38BFC5191Q37773291-DB6FFE5B-C33F-4C63-9A84-CB4F15C06D50Q38032598-FE0625B6-A0EE-46AE-9EA8-1953180CBFE5Q38066586-C6385352-52E7-4E3C-9AA3-29D265DC8A61Q38150110-BEC5C00F-B8B3-4DDF-89E0-BFDB690B71A7Q38152797-0474DC32-C227-4B09-AF67-05B8F8059CA7Q38174023-71014709-A316-418D-AD58-79373ABD88C8Q38590248-DD55BD6E-825B-4635-BE93-D807D5B219B6Q38650724-9EFEF134-4C76-48A5-8576-70F705CBB750Q38763327-BA5D4E62-DE74-4A5E-80E4-A431329A17C6
P2860
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@ast
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@en
type
label
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@ast
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@en
prefLabel
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@ast
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@en
P2860
P1433
P1476
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
@en
P2093
D T Boumpas
P I Sidiropoulos
P2860
P304
P356
10.1191/0961203304LU1032OA
P577
2004-01-01T00:00:00Z